PFS Non-inferior with Fixed-Duration Treatment with Venetoclax-Obinutuzumab or Venetoclax-Ibrutinib to Continuous Ibrutinib in Patients with Previously Untreated CLL By Ogkologos - December 17, 2025 351 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the CLL17 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in... July 16, 2025 A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells... April 26, 2024 Woman Creates Non-Toxic Nail Polish Brand After Her Mom’s Breast Cancer... November 20, 2020 Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... October 15, 2021 Load more HOT NEWS Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients... Immunoscore Classification Significantly Associates with Time to Recurrance In Asian Patients... FDA Approves Brentuximab Vedotin in Combination with Chemotherapy for Paediatric Patients... In Mouse Study, KRAS-Targeted Drug Shows Potential against Pancreatic Cancer
